Susquehanna International Group
ONCT

Susquehanna International Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Susquehanna International Group’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,370
Closed -$531K – 14154
2021
Q3 		$531K Buy
6,370
+4,705
+283% +$389K ﹤0.01% 9234
2021
Q2 		$158K Sell
1,665
-2,505
-60% -$297K ﹤0.01% 11816
2021
Q1 		$694K Buy
4,170
+2,845
+215% +$376K ﹤0.01% 8678
2020
Q4 		$130K Buy
+1,325
New +$83.8K ﹤0.01% 10350
2019
Q1 		– Sell
-91
Closed -$10K – 10092
2018
Q4 		$10K Sell
91
-104
-53% -$20.8K ﹤0.01% 8746
2018
Q3 		$43K Buy
+195
New +$468K ﹤0.01% 8887
2015
Q4 		– Sell
-11
Closed -$12K – 10114
2015
Q3 		$12K Sell
11
-3
-21% -$4.38K ﹤0.01% 9536
2015
Q2 		$29K Buy
14
+3
+27% +$4.26K ﹤0.01% 9955
2015
Q1 		$10K Sell
11
-4
-27% -$3.98K ﹤0.01% 9310
2014
Q4 		$15K Sell
15
-16
-52% -$14.3K ﹤0.01% 9499
2014
Q3 		$32K Buy
31
+1
+3% +$1.47K ﹤0.01% 9290
2014
Q2 		$59K Buy
30
+12
+67% +$23.7K ﹤0.01% 9568
2014
Q1 		$39K Sell
18
-31
-63% -$77.2K ﹤0.01% 8734
2013
Q4 		$113K Sell
49
-26
-35% -$59.5K ﹤0.01% 8584
2013
Q3 		$212K Sell
75
-270
-78% -$1.34M ﹤0.01% 7697
2013
Q2 		$3.19M Buy
+345
New +$2.66M ﹤0.01% 3197

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $786M AUM 19.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Susquehanna International Group's ONCT Position: Q3 2024 in Review

Susquehanna International Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2024, closing a stake of 15,206 shares — an estimated $116K sold.

Susquehanna International Group first reported a position in ONCT in Q2 2013 and held it in 27 quarters. The position peaked at $4.17M in Q1 2021. 23 funds tracked by Wall St. Rank hold ONCT as of Q3 2024.

  • Susquehanna International Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 15,206 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $116K.
  • Susquehanna International Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
  • Susquehanna International Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $4.17M in Q1 2021.
  • 23 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.